Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Moved Down to Buy by Wall Street Zen

Wall Street Zen cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday,Wall Street Zen reports.

A number of other analysts have also issued reports on AMPH. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Barclays upped their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th. Weiss Ratings raised Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 16th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wells Fargo & Company raised their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Reduce” and an average price target of $22.50.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $27.72 on Friday. The business has a fifty day moving average of $24.76 and a 200-day moving average of $22.31. The company has a market cap of $1.18 billion, a P/E ratio of 16.40, a PEG ratio of 5.41 and a beta of 0.90. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $29.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. As a group, equities research analysts expect that Amphastar Pharmaceuticals will post 2.43 EPS for the current year.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard Prins sold 7,973 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the completion of the sale, the director directly owned 29,625 shares in the company, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO William Peters sold 8,180 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the transaction, the chief financial officer owned 172,846 shares in the company, valued at $3,885,578.08. The trade was a 4.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 33,479 shares of company stock worth $763,922. Insiders own 29.60% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its holdings in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after acquiring an additional 228,262 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Amphastar Pharmaceuticals by 1.7% during the first quarter. Renaissance Technologies LLC now owns 553,900 shares of the company’s stock worth $10,851,000 after buying an additional 9,200 shares during the period. Systematic Financial Management LP lifted its stake in shares of Amphastar Pharmaceuticals by 4.0% in the first quarter. Systematic Financial Management LP now owns 452,898 shares of the company’s stock valued at $8,872,000 after buying an additional 17,318 shares in the last quarter. Bridge City Capital LLC raised its holdings in shares of Amphastar Pharmaceuticals by 13.3% in the 3rd quarter. Bridge City Capital LLC now owns 383,901 shares of the company’s stock worth $9,908,000 after purchasing an additional 45,193 shares during the period. Finally, Denali Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 41.1% in the second quarter. Denali Advisors LLC now owns 375,965 shares of the company’s stock valued at $7,587,000 after acquiring an additional 109,500 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.